Over ten years after Washington and Colorado led the way in legalizing recreational marijuana, the cannabis industry has grown significantly. What began as a small market is now a billion-dollar sector in the United States. This rapid growth has brought a variety of new products to mainstream retail, including psychoactive items that range from pharmaceuticals to wellness goods. However, this expansion is not without its challenges.
With more products on the market, the number of lawsuits and liability issues has also increased, raising concerns for insurance providers. One major issue is the emergence of substances sold alongside cannabis, such as hemp-derived cannabinoids and psychedelics. These products often lack clear regulations and standardized testing, making them hard to insure. Lee Woodruff, a leader in cannabis practice at Jencap Insurance Services, pointed out that insurers are particularly cautious about these new offerings due to the uncertainties surrounding their long-term effects and risks.
Among the products gaining popularity is kratom, a plant from Southeast Asia known for its stimulant and opioid-like effects. It is marketed as a natural remedy for pain and anxiety, but the evidence supporting its use is limited. Kratom is not classified as a controlled substance by the FDA, which adds to the uncertainty for both consumers and insurers. Woodruff noted that many CBD retail shops are now selling kratom, but the lack of federal oversight creates unease for insurance companies.
Psychedelics are also becoming more prominent, especially after Oregon and Colorado approved psilocybin for therapeutic use. While clinical trials are showing promise for treating conditions like depression and PTSD, these therapies carry risks. Incidents of adverse reactions have raised alarms, prompting insurers to be cautious. Woodruff mentioned that while there is interest in covering psychedelics, many companies are still in early research stages, making insurance difficult.
Hemp-derived products like Delta-8 and Delta-9 THC are booming as well, but they are under regulatory scrutiny. Delta-8, which is derived from CBD and marketed as a milder alternative to marijuana, has been sold widely due to a loophole in the 2018 Farm Bill. States are now working to establish regulations around these products, with Texas currently debating how to handle Delta-8.
Looking ahead, the market for product liability insurance in the cannabis sector remains competitive, with rates currently low due to limited claims history. However, Woodruff warned that this might create a false sense of security, as the potential risks are significant. Operators face financial pressures, especially in oversaturated markets, leading some to forgo insurance altogether. This could result in higher premiums concentrated among larger businesses as smaller ones struggle to survive in a challenging market.
As the cannabis industry continues to evolve, both businesses and insurance providers will need to adapt to the changing landscape, balancing growth with the need for safety and regulation.